The Pharmaceutical Journal
Vol 277 No 7428 p629
25 November 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

New medicine for urinary incontinence launched

Novartis has launched a new treatment for urinary incontinence. Darifenacin (Emselex), a urinary antispasmodic, is intended to treat urge incontinence, increased urinary frequency and urgency that may occur in patients with overactive bladder syndrome.

Last month, the National Institute for Health Clinical Excellence recommended that darifenacin be considered as an alternative for patients intolerant of immediate-release oxybutynin (PJ, 28 October, p506).


Notice-board p633